Faron Pharmaceuticals Oy Share Discussion Threads

[itsallamess] 12/10/2019 08:51

'All I know for sure (said by Markku) is that he wants to retain a degree of control'

That sounds like where the discussions for clevegen partner hinges on... How much control Marku wants to give up...

All in all we are in for a rise in share price when the partner signs up

[itsallamess] 11/10/2019 11:24

It's just on traukamine Marku has said the next trial period would be financed by an outside source and on clevergen they will get a partner on board which seems like what the 20 percent more shares would be for

[hashertu] 11/10/2019 10:59

litsallamess.

The company have cash till Q1 2020, so they need at least another 12 months worth of cash. If Traumakine goes on the back burner, then the cash needed would be less, but I think they would need to gather more evidence to support their CS/traumakine hypothesis before a 3rd party would fund a Ph III trial.
The money required to fund Clevegen trials is probably much greater than they could raise by share issue. If they have deep-pocketed pharma knocking at their door, then get them to pay.
In answer to your question, that is my supposition.
All I know for sure (said by Markku) is that he wants to retain a degree of control, and be involved in the process, over how Clevegen is developed.

[itsallamess] 11/10/2019 10:22

Hashertu

why do you think the money is for T and not clevergen?

[colin12345678] 11/10/2019 09:55

Thanks Hash sounded positive then

[hashertu] 11/10/2019 09:42

I went to Proactive Investor last night.
Markku (in Q&A) said that is possible that Clevegen could be available in the market as soon as 2023. I think it was said in the context of Colorectal cancer, where patients have failed all other lines of treatment, which would allow a significantly shorter approval process.
I asked him about the reason for calling the EGM so soon after the recent placing, and what was referred to in the Notice, section B, "events after preparation ...". Traumakine manufacturing is the reason.
At the EGM, they are seeking authority to issue 7.8m shares, and removing authority from 7.1m. Markku seemed to think it normal company practice.
I have not read all the small print, but suspect that the rules governing how they can issue those shares is changed. Or more importantly, to whom.
Markku is still very excited about Clevegen in his presentation.
If I had to hazard a guess (Markku did not say or hint), I would say that a partner has been lined up for Clevegen. As a minimum they will take a significant stake in Faron (up to 20%) and probably pay for some/all of the Clevegen program in isolation or in combination with their own drugs.
The conversations with the FDA/Traumakine/cortico steroids are quite advanced. The FDA have taken the Faron assessment of the use of CS and their effects very seriously. I got the impression that a statement was imminent.
Anyway, the cash from (possible) placing might be enough to test Traumakine with CS.

[itsallamess] 11/10/2019 07:02

Daffod

It clear that you know very little about what's going on with Faron

I suggest you read the RNS and educate yourself and then you will see the reason why the share price is on the rise.

I take it you are unaware of the partner discussions with a major pharma to be concluded in H2 and the purpose of the EGM?

If you did then your comments putting down the 2 drugs would be something you would consider foolish

[daffodil4] 10/10/2019 23:01

The RNS deatails very early days trial news..
IMO This comapany has no funds to progress either
of their drugs...I think Traumakine is unlikely
to be commercial...it does not have the goahead
for another trial currently..and Clevegen has
only reported results on a handful of patients.
The EGM is significant..not sure what the outcome
will be, but I would not invest here without knowing
as currently they only have funds for another few months..

[milliecusto] 10/10/2019 15:59

That's a good thing

[soulected] 10/10/2019 15:52

Is the rise just due to the new lower dose trial RNS?

[davidlloyd] 10/10/2019 15:50

Some tumbleweed just rolled by. Surprised this BB is so deserted at the mo......


DL

[itsallamess] 04/10/2019 09:09

The money could be for a partner for clevegen. They are in partner discussions with someone. A neat 20% of shares they want to give away.

[hashertu] 04/10/2019 08:53

I, too, am unclear about what is going on.
Faron cannot manufacture themselves, so what is the money for?

[itsallamess] 04/10/2019 08:46

Lost a partner? That's not correct

[monster500] 04/10/2019 08:36

They just lost a partner! Hence share drop.

[itsallamess] 04/10/2019 08:16

20% more share. This is for a new partner who will inject funds into the company and expertise

[itsallamess] 04/10/2019 08:07

Not sure of the purpose? To replace the directors rights to issue more shares that was granted in May. To replace that amount for slightly more.

Not such a big deal

[monster500] 04/10/2019 07:43

Views on EGM ANYONE?

[latifs100] 02/10/2019 18:51

have people moved on. no comments since 24 july??

[this1] 24/7/2019 15:08

FYIhttps://www.fiercebiotech.com/biotech/gsk-drops-lung-injury-drugs-as-respiratory-clear-out-continues

[newtothisgame3] 13/7/2019 07:38

Stock Watch #FARN - #Faron #Pharmaceuticals - Faron Pharmaceuticals has hailed encouraging results ..

[ny boy] 12/7/2019 12:40

Great progress in since last July, added on the pull back, onwards we go on increasingly good news flow. Got (STX) from mid 30’s, that one going well, now just awaiting fda decision by 27 July, for a vertical rise! Some good plays around in these markets

[sportbilly1976] 05/7/2019 10:12

would imagine just a large buyer in the background wanting in quick.

sp moves are rapid and on little 'reported' volume.

[davidlloyd] 05/7/2019 09:59

No it would seem. Still recovering quickly

DL